ArticleIranian journal of pharmaceutical research : IJPR
Comparison of Naringenin and Alendronate in the Attenuation of Ovariectomy-Induced Osteoporosis by Modulating Autophagy, Apoptosis, and Oxidative Stress in Rats.
Article in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Estrogen deficiency after menopause is a major driver of osteoporosis and has been increasingly linked to dysregulated cellular stress responses, including autophagy and apoptosis, that affect bone remodeling and microarchitecture. Objectives: This study aimed to evaluate the therapeutic effects of naringenin (NA) and alendronate (AL) on ovariectomy (OVX)-induced osteoporosis in rats, with emphasis on autophagy- and apoptosis-related molecular signatures. Methods: Female Sprague-Dawley rats were assigned to sham-operated (SH), OVX, OVX+NA (50 mg/kg/day), or OVX+AL (5 µg/kg/day) groups (n = 10/group) and were treated by oral gavage for 10 weeks. Bone health markers, including bone cell numbers and trabecular weight and volume, were assessed using stereology. Serum estradiol and osteocalcin levels were assayed by enzyme-linked immunosorbent assay. Oxidative markers, including catalase (CAT) and glutathione reductase (GR) activities, were measured using spectrophotometric assays. Femoral mRNA expression of microtubule-associated protein 1 light chain 3 (LC3), beclin 1 (BECN1), autophagy-related 5 (ATG5), caspase 9 (CASP9), and B-cell lymphoma 2 (BCL2) was quantified by reverse transcription quantitative polymerase chain reaction. Results: Ovariectomy reduced estradiol levels compared with SH, and estradiol was not restored by NA or AL. Both treatments mitigated OVX-associated changes in osteocalcin and improved femoral stereological/histomorphometric outcomes, with AL exerting a greater effect across multiple structural and molecular outcomes. NA, but not AL, significantly increased CAT and GR activities relative to OVX. Ovariectomy increased CASP9 and autophagy markers and decreased BCL2; both treatments shifted these transcripts toward SH values, with a stronger effect for AL. Conclusions: Naringenin and AL mitigated OVX-associated osteoporotic changes without restoring systemic estradiol levels, and these effects were accompanied by shifts in apoptosis- and autophagy-related gene expression. These findings suggest that the beneficial effects of AL and NA may be associated with the modulation of oxidative stress and apoptosis- and autophagy-related mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.